Brand  (β version)

  The number of atoms exceeds 100,000.
  So, it can not be displayed here.

Select unit:

Select hetatm:   

close
information
centroid:
interaction residue:

Select chain:   Sequence  

Data format:   

Color scheme of protein:

Ligands
Code Name Style Show Link
9QW (4~{S})-5-(5-chloranyl-1-methyl-2-oxidanylidene-pyridin-3-yl)-4-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4~{H}-pyrrolo[3,4-D]imidazol-6-one
CL Chloride ion
Non-standard Residues
Code Name Show
Glycosylation
Code Name Emphasize
Modification
Code Name Show
Code : 5OC8   PDBj   RCSB PDB   PDBe
Header : LIGASE
Title : HDM2 (17-111, WILD TYPE) COMPLEXED WITH NVP-HDM201 AT 1.56A
Release Data : 2018-08-22
Compound :
mol_id molecule chains synonym
1 E3 ubiquitin-protein ligase Mdm2 A Double minute 2 protein,Hdm2,Oncoprotein Mdm2,RING-type E3 ubiquitin transferase Mdm2,p53-binding protein Mdm2
ec: 2.3.2.27
fragment: N-terminal domain, p53 binding domain
Source :
mol_id organism_scientific organism_common expression_system
1 Homo sapiens  (taxid:9606) Human Escherichia coli BL21  (taxid:511693)
gene: MDM2
expression_system_vector_type: plasmid
expression_system_plasmid: pET28-derived vector
Authors : Kallen, J.
Keywords : PPI WITH P53, INHIBITOR COMPLEX, CELL CYCLE, LIGASE
Exp. method : X-RAY DIFFRACTION ( 1.5600 Å )
Citation :

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Jeay, S.,Ferretti, S.,Holzer, P.  et al.
(2018)  Cancer Res.  78 : 6257 - 6267

PubMed: 30135191
DOI: 10.1158/0008-5472.CAN-18-0338

Chain : A
UniProt : Q00987 (MDM2_HUMAN)
Reaction: EC: Evidence:
Physiological Direction:
S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine. 2.3.2.27 PubMed:12821780
-